<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548095" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548095/" /><meta name="ncbi_pagename" content="Ezetimibe - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Ezetimibe - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Ezetimibe" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2018/02/18" /><meta name="citation_pmid" content="31643425" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548095/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Ezetimibe" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2018/02/18" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548095/" /><meta name="description" content="Ezetimibe is an inhibitor of intestinal cholesterol absorption that is widely used in the therapy of hypercholesterolemia, usually in combination with other agents. Ezetimibe therapy is associated with a low rate of serum aminotransferase elevations and clinically apparent liver injury due to ezetimibe occurs, but is rare." /><meta name="og:title" content="Ezetimibe" /><meta name="og:type" content="book" /><meta name="og:description" content="Ezetimibe is an inhibitor of intestinal cholesterol absorption that is widely used in the therapy of hypercholesterolemia, usually in combination with other agents. Ezetimibe therapy is associated with a low rate of serum aminotransferase elevations and clinically apparent liver injury due to ezetimibe occurs, but is rare." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548095/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Ezetimibe/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548095/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE89054004657D610000000009A802E7.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548095_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548095_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Exenatide/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Ezogabine/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548095_"><span class="title" itemprop="name">Ezetimibe</span></h1><p class="small">Last Update: <span itemprop="dateModified">February 18, 2018</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Ezetimibe.OVERVIEW"><h2 id="_Ezetimibe_OVERVIEW_">OVERVIEW</h2><div id="Ezetimibe.Introduction"><h3>Introduction</h3><p>Ezetimibe is an inhibitor of intestinal cholesterol absorption that is widely used in the therapy of hypercholesterolemia, usually in combination with other agents. Ezetimibe therapy is associated with a low rate of serum aminotransferase elevations and clinically apparent liver injury due to ezetimibe occurs, but is rare.</p></div><div id="Ezetimibe.Background"><h3>Background</h3><p>Ezetimibe (e zet' i mibe) is a synthetic azetidinone that inhibits cholesterol absorption from the intestine. Ezetimibe acts by binding to and inhibiting the Niemann-Pick C1-like 1 protein (NPC1), the major transporter of cholesterol in the intestinal brush border. Ezetimibe by itself lowers serum cholesterol, but the inhibition of cholesterol absorption is usually followed by a compensatory increase in hepatic cholesterol synthesis, a response that can be blocked by hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors [statins]. For this reason, ezetimibe is commonly used in combination with a statin. Addition of ezetimibe to a maximized dose of statins generally lowers LDL-cholesterol levels by 22% to 24%. Ezetimibe was approved for use in the United States in 2002 and is usually recommended as an adjunctive therapy to diet or in combination with a statin in management of patients with hypercholesterolemia at high risk for cardiovascular or cerebrovascular disease. It is also used alone in patients who are intolerant of statins and can be combined with other lipid-lowering agents (such as fibrates or anti-PCSK9 monoclonal antibodies). Ezetimibe is available in 10 mg tablets under the brand name Zetia and the usually recommended dose is 10 mg daily. Ezetimibe is also available in a fixed combination with simvastatin (20 or 40 mg) under the trade name Vytorin and with atorvastatin (10, 20, 40 or 80 mg) under the trade name Liptruzet. Ezetimibe has achieved wide scale acceptance and several million prescriptions are filled yearly. Common side effects of ezetimibe include diarrhea and flatulence. Rare, potentially severe adverse effects include hypersensitivity reactions, myopathy and rhabdomyolysis.</p></div><div id="Ezetimibe.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Therapy with ezetimibe alone or in combination with other lipid lowering agents is associated with a low rate of serum enzyme elevations (0.5% to 1.5%), but most elevations were self-limited and not associated with jaundice or symptoms. In large randomized controlled trials, ezetimibe by itself has not been associated with a higher rate of serum <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevation than occurs with placebo therapy. However, the addition of ezetimibe to statin therapy has been associated with a slight increase in the likelihood of serum aminotransferase elevations or rates of discontinuation due to liver test abnormalities. Clinically apparent acute liver injury due to ezetimibe has been reported, but is rare. Furthermore, because this agent is often used in combination with other cholesterol lowering drugs, the role of ezetimibe in these reports is not always well defined. The latency to onset of clinically apparent liver injury attributed to ezetimibe has ranged from 2 to 10 months and the pattern of serum enzyme elevations has ranged from hepatocellular to cholestatic. Cases of autoimmune hepatitis-like injury have been described in patients taking the combination of ezetimibe and a statin, and the role of ezetimibe in these reactions is difficult to assign (Case 1). A single instance of vanishing bile duct syndrome due to ezetimibe has been described in a patient who continued on ezetimibe for several months despite presence of jaundice.</p><p>Likelihood score: C (probable rare cause of clinically apparent liver injury).</p></div><div id="Ezetimibe.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>Ezetimibe is metabolized by the P450 system, but has little effect on the pharmacokinetics of other drugs, perhaps because it is rapidly conjugated and excreted in the bile as a glucuronide. Cases of an autoimmune hepatitis-like syndrome suggest immune mediated injury may be the cause of some clinically apparent liver injury due to ezetimibe.</p></div><div id="Ezetimibe.Outcome_and_Management"><h3>Outcome and Management</h3><p>The mild <a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> elevations associated with ezetimibe therapy are usually self-limited and do not require dose modification. Cases of acute liver injury due to ezetimibe have usually been self-limited, but instances of vanishing bile duct syndrome, chronic autoimmune hepatitis and acute liver failure (Case 2) have been reported. Patients with autoimmune hepatitis-like liver injury due to ezetimibe may warrant corticosteroid therapy, but the dose and duration of therapy should be kept to a minimum. The product label for ezetimibe includes a warning about enzyme elevations during combination therapy and recommends monitoring of liver tests before and during treatment. Ezetimibe has a unique mechanism of action and chemical structure, and there is no reason to suspect cross sensitivity to liver injury between ezetimibe and other cholesterol lowering agents. Ezetimibe is often used in patients with intolerance to statins becaue of muscle pains and myopathy.</p><p>Drug Class: <a href="/books/n/livertox/Lipid-LoweringAgents/">Antilipemic Agents</a></p><p>Other Drugs in the Subclass, <a href="/books/n/livertox/Statins/">Statins</a>: <a href="/books/n/livertox/Atorvastatin/">Atorvastatin</a>, <a href="/books/n/livertox/Fluvastatin/">Fluvastatin</a>, <a href="/books/n/livertox/Lovastatin/">Lovastatin</a>, <a href="/books/n/livertox/Pitavastatin/">Pitavastatin</a>, <a href="/books/n/livertox/Pravastatin/">Pravastatin</a>, <a href="/books/n/livertox/Rosuvastatin/">Rosuvastatin</a>, <a href="/books/n/livertox/Simvastatin/">Simvastatin</a></p></div></div><div id="Ezetimibe.CASE_REPORTS"><h2 id="_Ezetimibe_CASE_REPORTS_">CASE REPORTS</h2><div id="Ezetimibe.Case_1._Autoimmune_hepatitis_l"><h3>Case 1. Autoimmune hepatitis like injury arising during atorvastatin and ezetimibe therapy.</h3><p>[Modified from: van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem 2005; 42: 402-4. <a href="https://www.ncbi.nlm.nih.gov/pubmed/16168199" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 50 year old woman developed nausea, abdominal pain and jaundice with features of autoimmune hepatitis during combination therapy with atorvastatin (80 mg daily for 16 months) and ezetimibe (10 mg daily for 3 months). There was no previous history of liver disease and laboratory tests had been normal shortly before ezetimibe was started. She had multiple other medical problems including coronary artery disease, osteoarthritis, hypothyroidism, and gastroesophageal reflux. She drank little alcohol and had no exposures to hepatitis. On presentation, she had epigastric tenderness but no rash or fever. Laboratory tests showed raised bilirubin and serum enzymes (Table). Both ezetimibe and atorvastatin were stopped. Tests for hepatitis A, B and C were negative and ultrasound imaging showed no evidence of biliary obstruction. She tested positive for antinuclear antibody and antibodies to double-stranded DNA (anti-dsDNA). A liver biopsy showed hepatitis with eosinophils and plasma cells. Over the ensuing few weeks, her symptoms resolved and laboratory tests improved. Six weeks after onset, her liver tests were normal and autoantibody levels had fallen. She was started on rosuvastatin for her hypercholesterolemia and did well without recurrence of symptoms or liver test abnormalities.</p><div id="Ezetimibe.Key_Points1"><h4>Key Points</h4><div id="Ezetimibe.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548095/table/Ezetimibe.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ezetimibe.T1_lrgtbl__"><table><thead><tr><th id="hd_h_Ezetimibe.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Medication:</th><td rowspan="1" colspan="1" style="vertical-align:top;">Ezetimibe (10 mg daily) and atorvastatin (80 mg daily)</td></tr></thead><tbody><tr><th headers="hd_h_Ezetimibe.T1_1_1_1_1" id="hd_b_Ezetimibe.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Ezetimibe.T1_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=10.7)</td></tr><tr><th headers="hd_h_Ezetimibe.T1_1_1_1_1" id="hd_b_Ezetimibe.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Ezetimibe.T1_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">3+ (jaundice, hospitalization)</td></tr><tr><th headers="hd_h_Ezetimibe.T1_1_1_1_1" id="hd_b_Ezetimibe.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Ezetimibe.T1_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">12 weeks for ezetimibe; 16 months for atorvastatin</td></tr><tr><th headers="hd_h_Ezetimibe.T1_1_1_1_1" id="hd_b_Ezetimibe.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Ezetimibe.T1_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">~6 weeks</td></tr><tr><th headers="hd_h_Ezetimibe.T1_1_1_1_1" id="hd_b_Ezetimibe.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Ezetimibe.T1_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Furosemide, diltiazem, diclofenac, acetaminophen, atenolol, ibuprofen, clopidogrel, thyroxine, lactulose, and nitrates</td></tr></tbody></table></div></div></div><div id="Ezetimibe.Laboratory_Values1"><h4>Laboratory Values</h4><div id="Ezetimibe.T2" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548095/table/Ezetimibe.T2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ezetimibe.T2_lrgtbl__"><table><thead><tr><th id="hd_h_Ezetimibe.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Ezetimibe.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Ezetimibe.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.aspartate-aminotransferase-ast-/">AST</a> (U/L)</th><th id="hd_h_Ezetimibe.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Ezetimibe.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Ezetimibe.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Ezetimibe.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pre</td><td headers="hd_h_Ezetimibe.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Ezetimibe.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">17</td><td headers="hd_h_Ezetimibe.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">75</td><td headers="hd_h_Ezetimibe.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.5</td><td headers="hd_h_Ezetimibe.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Atorvastatin 80 mg (13 months)</td></tr><tr><td headers="hd_h_Ezetimibe.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Ezetimibe.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Ezetimibe.T2_1_1_1_3 hd_h_Ezetimibe.T2_1_1_1_4 hd_h_Ezetimibe.T2_1_1_1_5 hd_h_Ezetimibe.T2_1_1_1_6" colspan="4" rowspan="1" style="vertical-align:top;">Ezetimibe (10 mg/day) started</td></tr><tr><td headers="hd_h_Ezetimibe.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">12 weeks</td><td headers="hd_h_Ezetimibe.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Ezetimibe.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1626</td><td headers="hd_h_Ezetimibe.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">468</td><td headers="hd_h_Ezetimibe.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">4.6</td><td headers="hd_h_Ezetimibe.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ANA 1:160, anti-dsDNA 38</td></tr><tr><td headers="hd_h_Ezetimibe.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">13 weeks</td><td headers="hd_h_Ezetimibe.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">10 days</td><td headers="hd_h_Ezetimibe.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">858</td><td headers="hd_h_Ezetimibe.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">424</td><td headers="hd_h_Ezetimibe.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">5.1</td><td headers="hd_h_Ezetimibe.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ANA 1:80, anti-dsDNA 31</td></tr><tr><td headers="hd_h_Ezetimibe.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">14 weeks</td><td headers="hd_h_Ezetimibe.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">15 days</td><td headers="hd_h_Ezetimibe.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">266</td><td headers="hd_h_Ezetimibe.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">340</td><td headers="hd_h_Ezetimibe.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">2.7</td><td headers="hd_h_Ezetimibe.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Ezetimibe.T2_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">18 weeks</td><td headers="hd_h_Ezetimibe.T2_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">45 days</td><td headers="hd_h_Ezetimibe.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">20</td><td headers="hd_h_Ezetimibe.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">100</td><td headers="hd_h_Ezetimibe.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.6</td><td headers="hd_h_Ezetimibe.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ANA 1:40, anti-dsDNA 6</td></tr><tr><td headers="hd_h_Ezetimibe.T2_1_1_1_1 hd_h_Ezetimibe.T2_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Ezetimibe.T2_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;42</b></td><td headers="hd_h_Ezetimibe.T2_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;130</b></td><td headers="hd_h_Ezetimibe.T2_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Ezetimibe.T2_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Ezetimibe.Comment1"><h4>Comment</h4><p>A well documented example of drug induced autoimmune hepatitis, with resolution when atorvastatin and ezetimibe were stopped. Particularly convincing was the decrease in autoantibody titers with drug withdrawal. Ezetimibe is perhaps the most likely candidate to have caused the liver injury, but cases of autoimmune hepatitis-like injury from atorvastatin have been reported with latency to onset of more than a year.</p></div></div><div id="Ezetimibe.Case_2._Acute_liver_failure_at"><h3>Case 2. Acute liver failure attributed to simvastatin and ezetimibe therapy.</h3><p>[Modified from: Tuteja S, Pyrsopoulos NT, Wolowich WR, Khanmoradi K, Levi DM, Selvaggi G, Weisbaum G, et al. Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. Pharmacotherapy 2008; 28: 1188-93. <a href="https://www.ncbi.nlm.nih.gov/pubmed/18752389" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PubMed Citation</a>]</p><p>A 70 year old woman developed abnormal liver tests ten weeks after switching from simvastatin (40 mg) monotherapy to the combination of simvastatin (40 mg) and ezetimibe (10 mg) daily. She had a history of coronary artery disease, hypertension, depression and hypercholesterolemia and had been on simvastatin for one and a half years with normal serum enzymes (Table). Despite stopping both simvastatin and ezetimibe when elevations in serum enzymes were first found, the patient developed jaundice and progressive symptoms of liver failure. Tests for hepatitis A, B and C were negative as were autoimmune markers. A liver biopsy showed changes suggestive of drug induced liver injury and severe cholestasis. She subsequently developed progressive encephalopathy and worsening coagulation indices, and was listed and underwent successful liver transplantation approximately 4 weeks after stopping therapy. In follow up for two years after transplantation, liver enzymes were normal.</p><div id="Ezetimibe.Key_Points2"><h4>Key Points</h4><div id="Ezetimibe.T3" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548095/table/Ezetimibe.T3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ezetimibe.T3_lrgtbl__"><table><thead><tr><th id="hd_h_Ezetimibe.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Medication:</th><td rowspan="1" colspan="1" style="vertical-align:top;">Ezetimibe and simvastatin</td></tr></thead><tbody><tr><th headers="hd_h_Ezetimibe.T3_1_1_1_1" id="hd_b_Ezetimibe.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pattern:</th><td headers="hd_b_Ezetimibe.T3_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Hepatocellular (R=25)</td></tr><tr><th headers="hd_h_Ezetimibe.T3_1_1_1_1" id="hd_b_Ezetimibe.T3_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">Severity:</th><td headers="hd_b_Ezetimibe.T3_1_1_2_1" rowspan="1" colspan="1" style="vertical-align:top;">5+ (emergency liver transplantation)</td></tr><tr><th headers="hd_h_Ezetimibe.T3_1_1_1_1" id="hd_b_Ezetimibe.T3_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_Ezetimibe.T3_1_1_3_1" rowspan="1" colspan="1" style="vertical-align:top;">10 weeks to liver test abnormalities, 12 weeks to jaundice</td></tr><tr><th headers="hd_h_Ezetimibe.T3_1_1_1_1" id="hd_b_Ezetimibe.T3_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">Recovery:</th><td headers="hd_b_Ezetimibe.T3_1_1_4_1" rowspan="1" colspan="1" style="vertical-align:top;">None</td></tr><tr><th headers="hd_h_Ezetimibe.T3_1_1_1_1" id="hd_b_Ezetimibe.T3_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Other medications:</th><td headers="hd_b_Ezetimibe.T3_1_1_5_1" rowspan="1" colspan="1" style="vertical-align:top;">Enalapril, escitalopram chronically</td></tr></tbody></table></div></div></div><div id="Ezetimibe.Laboratory_Values2"><h4>Laboratory Values</h4><div id="Ezetimibe.T4" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548095/table/Ezetimibe.T4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ezetimibe.T4_lrgtbl__"><table><thead><tr><th id="hd_h_Ezetimibe.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Time After Starting</th><th id="hd_h_Ezetimibe.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Time After Stopping</th><th id="hd_h_Ezetimibe.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a> (U/L)</th><th id="hd_h_Ezetimibe.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Alk P (U/L)</th><th id="hd_h_Ezetimibe.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a> (mg/dL)</th><th id="hd_h_Ezetimibe.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Ezetimibe.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Pre</td><td headers="hd_h_Ezetimibe.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Ezetimibe.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">19</td><td headers="hd_h_Ezetimibe.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">65</td><td headers="hd_h_Ezetimibe.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.5</td><td headers="hd_h_Ezetimibe.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Before starting simvastatin</td></tr><tr><td headers="hd_h_Ezetimibe.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Ezetimibe.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Ezetimibe.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">14</td><td headers="hd_h_Ezetimibe.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">51</td><td headers="hd_h_Ezetimibe.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.4</td><td headers="hd_h_Ezetimibe.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">On simvastatin before ezetimibe</td></tr><tr><td headers="hd_h_Ezetimibe.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">10 weeks</td><td headers="hd_h_Ezetimibe.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">0</td><td headers="hd_h_Ezetimibe.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">842</td><td headers="hd_h_Ezetimibe.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"></td><td headers="hd_h_Ezetimibe.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.4</td><td headers="hd_h_Ezetimibe.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Simvastatin &#x00026; ezetimibe stopped</td></tr><tr><td headers="hd_h_Ezetimibe.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">12 weeks</td><td headers="hd_h_Ezetimibe.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">2 weeks</td><td headers="hd_h_Ezetimibe.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">2595</td><td headers="hd_h_Ezetimibe.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">217</td><td headers="hd_h_Ezetimibe.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">15.8</td><td headers="hd_h_Ezetimibe.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">Admitted</td></tr><tr><td headers="hd_h_Ezetimibe.T4_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">14 weeks</td><td headers="hd_h_Ezetimibe.T4_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">4 weeks</td><td headers="hd_h_Ezetimibe.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">1951</td><td headers="hd_h_Ezetimibe.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">116</td><td headers="hd_h_Ezetimibe.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">21.6</td><td headers="hd_h_Ezetimibe.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">INR=2.0</td></tr><tr><td headers="hd_h_Ezetimibe.T4_1_1_1_1 hd_h_Ezetimibe.T4_1_1_1_2 hd_h_Ezetimibe.T4_1_1_1_3 hd_h_Ezetimibe.T4_1_1_1_4 hd_h_Ezetimibe.T4_1_1_1_5 hd_h_Ezetimibe.T4_1_1_1_6" colspan="6" rowspan="1" style="vertical-align:top;">Emergency liver transplantation performed</td></tr><tr><td headers="hd_h_Ezetimibe.T4_1_1_1_1 hd_h_Ezetimibe.T4_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;">Post-op day 1</td><td headers="hd_h_Ezetimibe.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">209</td><td headers="hd_h_Ezetimibe.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">83</td><td headers="hd_h_Ezetimibe.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">8.4</td><td headers="hd_h_Ezetimibe.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Ezetimibe.T4_1_1_1_1 hd_h_Ezetimibe.T4_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;">Post-op day 23</td><td headers="hd_h_Ezetimibe.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">39</td><td headers="hd_h_Ezetimibe.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">82</td><td headers="hd_h_Ezetimibe.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">1.0</td><td headers="hd_h_Ezetimibe.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Ezetimibe.T4_1_1_1_1 hd_h_Ezetimibe.T4_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;">2 years after transplant</td><td headers="hd_h_Ezetimibe.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">18</td><td headers="hd_h_Ezetimibe.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">79</td><td headers="hd_h_Ezetimibe.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">0.5</td><td headers="hd_h_Ezetimibe.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr><tr><td headers="hd_h_Ezetimibe.T4_1_1_1_1 hd_h_Ezetimibe.T4_1_1_1_2" colspan="2" rowspan="1" style="vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_Ezetimibe.T4_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;56</b></td><td headers="hd_h_Ezetimibe.T4_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;126</b></td><td headers="hd_h_Ezetimibe.T4_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_Ezetimibe.T4_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Ezetimibe.Comment2"><h4>Comment</h4><p>The onset of injury 10 weeks after starting ezetimibe suggests that it was the cause of the acute liver injury, but onset of hepatitis due to simvastatin can occur months to years after its initiation. Since ezetimibe is usually used in combination with a statin, it is usually difficult to attribute the liver injury to ezetimibe alone. This is one of the few case reports of acute liver failure due to a cholesterol lowering agent.</p></div></div></div><div id="Ezetimibe.PRODUCT_INFORMATION"><h2 id="_Ezetimibe_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><div id="Ezetimibe.BPI" class="box"><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Ezetimibe &#x02013; Zetia&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antilipemic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=ezetimibe" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div></div><div id="Ezetimibe.CHEMICAL_FORMULA_AND_STRUCTURE"><h2 id="_Ezetimibe_CHEMICAL_FORMULA_AND_STRUCTURE_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Ezetimibe.T5" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548095/table/Ezetimibe.T5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Ezetimibe.T5_lrgtbl__"><table><thead><tr><th id="hd_h_Ezetimibe.T5_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">DRUG</th><th id="hd_h_Ezetimibe.T5_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Ezetimibe.T5_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Ezetimibe.T5_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Ezetimibe.T5_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Ezetimibe</td><td headers="hd_h_Ezetimibe.T5_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135107180" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">163222-33-1</a></td><td headers="hd_h_Ezetimibe.T5_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">C24- H21-F2-N-O3</td><td headers="hd_h_Ezetimibe.T5_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><div class="graphic"><img src="/books/NBK548095/bin/Ezetimibe.jpg" alt="Image of Chemical Structure" /></div></td></tr></tbody></table></div></div></div><div id="Ezetimibe.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Ezetimibe_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 18 February 2018</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Ezetimibe.R1">De Marzio DH, Navarro VJ. Hepatotoxicity of cardiovascular and antidiabetic medications. Lipid lowering agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 519-40.<div><i>(Review of hepatotoxicity of lipid lowering agents mentions that cases of severe cholestatic, as well as autoimmune, hepatitis have been linked to ezetimibe use).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R2">Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 877-908.<em>
</em><div><i>(Textbook of pharmacology and therapeutics; ezetimibe inhibits a specific transport process in jejunal enterocytes which take up cholesterol from the lumen, ezetimibe also inhibits intestinal absorption of plant sterols).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R3">Gagn&#x000e9; C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105: 2469-75.  [<a href="/pubmed/12034651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12034651</span></a>]<div><i>(Prospective trial comparing the combination of ezetimibe and either atorvastatin or simvastatin to the statin alone in 50 patients with homozygous familial hypercholesterolemia; side effects were similar, one patients on combination therapy and one on statins alone had ALT elevations above 3 times ULN, but both resolved).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R4">Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, Johnson-Levonas AO, et al.; Ezetimibe Study Group. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 2004; 26: 1758-73.  [<a href="/pubmed/15639688" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15639688</span></a>]<div><i>(Controlled trial of various doses of ezetimibe, simvastatin or the combination vs placebo for 12 weeks in 1528 patients with hypercholesterolemia; confirmed ALT elevations above 3 times ULN occurred in 0.7% on placebo, 0.7% on ezetimibe alone, 1.1% on simvastatin alone and 1.5% on the combination).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R5">Masana L, Mata P, Gagn&#x000e9; C, Sirah W, Cho M, Johnson-Levonas AO, Meehan A, et al.; Ezetimibe Study Group. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin Ther 2005; 27: 174-84.  [<a href="/pubmed/15811480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15811480</span></a>]<div><i>(Trial comparing addition of ezetimibe vs placebo to ongoing simvastatin therapy for hypercholesterolemia for up to 48 weeks; only one instance of ALT levels above 3 times ULN and no case of clinically apparent liver injury in 355 patients on the combination).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R6">Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005; 44: 467-94.  [<a href="/pubmed/15871634" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15871634</span></a>]<div><i>(Review of biochemistry, pharmacology, mechanism of action, drug interactions of ezetimibe; ezetimibe is extensively conjugated to glucuronide in the intestine and liver and while it has inhibitory activity against CYP 3A4, it does not exhibit major drug-drug interactions with other agents that are metabolized by this pathway).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R7">van Heyningen C. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem 2005; 42: 402-4.  [<a href="/pubmed/16168199" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16168199</span></a>]<div><i> (50 year old woman developed jaundice 16 months after starting atorvastatin and 3 months after starting ezetimibe therapy [bilirubin 4.6 mg/dL, AST 1626 U/L, Alk P 468 U/L, positive ANA and anti-dsDNA], resolving 6 weeks after stopping both: Case 1).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R8">Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149: 464-73.  [<a href="/pubmed/15864235" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15864235</span></a>]<div><i>(Controlled trial of ezetimibe/simvastatin vs atorvastatin in 1902 patients with hypercholesterolemia, ALT elevations above 3 times ULN occurred in 1.1% on atorvastatin and none on ezetimibe/simvastatin).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R9">Stolk MF, Becx MC, Kuypers KC, Seldenrijk CA. Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol 2006; 4: 908-11.  [<a href="/pubmed/16797241" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16797241</span></a>]<div><i>(Two patients with severe but clinically distinct liver injury; 52 year old woman developed jaundice 4 months after ezetimibe was added to atorvastatin therapy, but both were continued for another 6 months [bilirubin 5.4 mg/dL, ALT 179 U/L, Alk P 1345 U/L] followed by a chronic cholestatic course and biopsy showing bile duct paucity; 58 year old man developed abdominal pain and nausea 2 months after adding ezetimibe to chronic atorvastatin therapy [bilirubin 0.9 mg/dL, ALT 575 U/L, Alk P 116 U/L, SMA positive], responding ultimately to a course of prednisone).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R10">Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis A, Edwards P, Tomassini JE, et al. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc. 2006; 81: 1579-88.  [<a href="/pubmed/17165637" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17165637</span></a>]<div><i>(Controlled trial of atorvastatin vs simvastatin/ezetimibe in 1229 patients with diabetes and hypercholesterolemia; confirmed ALT elevations above 3 times ULN occurred in 0.3% of atorvastatin vs no simvastatin/ezetimibe treated patients, and no clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R11">Bhardwah SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis 2007; 11: 597-613.  [<a href="/pmc/articles/PMC2048990/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2048990</span></a>] [<a href="/pubmed/17723922" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17723922</span></a>]<div><i>(Review of hepatotoxicity of lipid lowering agents; cases of acute cholestatic and autoimmune hepatitis-like injury from ezetimibe have been reported).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R12">Ose L, Johnson-Levonas A, Reyes R, Lin J, Shah A, Tribble D, Musliner T; Vytorin Extension Study Group. A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. Int J Clin Pract 2007; 61: 1469-80.  [<a href="/pubmed/17655686" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17655686</span></a>]<div><i>(Continuation of trial described by Bayes [2004] with 1104 patients continuing in an extension study of simvastatin vs simvastatin/ezetimibe in various dosages; confirmed ALT elevations above 3 times ULN occurred in 1.3% on simvastatin alone and 1.5% on the combination; no cases of clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R13">Tuteja S, Pyrsopoulos NT, Wolowich WR, Khanmoradi K, Levi DM, Selvaggi G, Weisbaum G, et al. Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation. Pharmacotherapy 2008; 28: 1188-93.  [<a href="/pubmed/18752389" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18752389</span></a>]<div><i>(70 year old woman developed acute liver failure 10 weeks after addition of ezetimibe to long term simvastatin therapy [1.5 years] [bilirubin 0.4 rising to 23.7 mg/dL, ALT 842 to 2595 U/L, Alk P 217 U/L], INR rising to 2.0 and emergency liver transplant: Case 2).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R14">Liu Q, Tobias H, Petrovic LM. Drug-induced liver injury associated with ezetimibe therapy. Dig Dis Sci 2007; 52: 602-5.  [<a href="/pubmed/17219067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17219067</span></a>]<div><i>(75 year old woman developed elevated liver tests 6 months after starting ezetimibe without a statin [bilirubin 0.9 mg/dL, ALT 731 U/L, Alk P 149 U/L, ANA 1:320], resolution within 4 months of stopping).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R15">Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008; 51: 1564-72.  [<a href="/pubmed/18420099" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18420099</span></a>]<div><i>(Controlled trial comparing niacin alone vs simvastatin/ ezetimibe vs all three for 24 weeks in 1220 patients with hypercholesterolemia; confirmed ALT elevations above 3 times ULN occurred in 0.4% on niacin, 0.4% on simvastastin/ezetimibe, and 0.5% on all three).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R16">Castellote J, Ariza J, Rota R, Girbau A, Xiol X. Serious drug-induced liver disease secondary to ezetimibe. World J Gastroenterol 2008; 14: 5098-9.  [<a href="/pmc/articles/PMC2742942/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2742942</span></a>] [<a href="/pubmed/18763297" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18763297</span></a>]<div><i>(56 year old woman developed jaundice and pruritus 2 months after starting ezetimibe without a statin or other lipid lowering medication [bilirubin 35.2 mg/dL, ALT 1575 U/L, Alk P 115 U/L], resolving within 4 weeks of stopping therapy).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R17">Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008; 62: 88-96.  [<a href="/pubmed/18173814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18173814</span></a>]<div><i>(Review of safety and toxicity of ezetimibe; rate of ALT elevations above 3 times ULN reported to be the same with ezetimibe as with placebo, but higher rates found with combinations of ezetimibe and statins [1.3% vs 0.4% with statin alone]; 4 cases of clinically apparent liver injury have appeared in the published literature).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R18">Ritchie SR, Orr DW, Black PN. Severe jaundice following treatment with ezetimibe. Eur J Gastroenterol Hepatol 2008; 20: 572-3.  [<a href="/pubmed/18467918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18467918</span></a>]<div><i>(49 year old woman developed jaundice 4 months after starting ezetimibe [bilirubin 37.8 mg/dL but ALT and Alk P normal], with cirrhosis on liver biopsy, high bilirubin levels fell to 2.1 mg/dL 4 months later; jaundice possibly related to competition between ezetimibe and bilirubin for excretion by MRP2, the protein deficient in Dubin-Johnson syndrome).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R19">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J; Drug-Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135: 1924-34.  [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, 3 cases were attributed to the combination of simvastatin and ezetimibe, but no details provided).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R20">Robinson JG, Ballantyne CM, Grundy SM, Hsueh WA, Parving HH, Rosen JB, Adewale AJ, et al. Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Am J Cardiol 2009; 103: 1694-702.  [<a href="/pubmed/19539078" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19539078</span></a>]<div><i>(Controlled trial of ezetimibe/simvastatin versus atorvastatin alone in 1128 patients with metabolic syndrome and hypercholesterolemia; adverse event rates were similar in the two groups, but consecutive ALT or AST elevations above 3 times ULN occurred in 0.3% of atorvastatin vs 1.4% of ezetimibe/simvastatin treated patients).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R21">McGinnis B, Schimmer J, Hutka K. An evaluation of alanine transaminase and creatine kinase elevations with the use of ezetimibe in an ambulatory care setting. J Clin Lipidol 2010; 4: 501-7.  [<a href="/pubmed/21122697" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21122697</span></a>]<div><i>(Among 4332 patients treated with ezetimibe in a ambulatory care setting, 44 [1.1%] had an ALT elevation above 3 times ULN, but many of the 44 had other reasons for the abnormalities).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R22">Foody JM, Brown WV, Zieve F, Adewale AJ, Flaim D, Lowe RS, Jones-Burton C, Tershakovec AM. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults &#x02265;65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). Am J Cardiol 2010; 106: 1255-63.  [<a href="/pubmed/21029821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21029821</span></a>]<div><i>(Among 1289 elderly patients with hypercholeseterolemia treated with atorvastatin or the combination of ezetimibe and simvastatin for 12 weeks, adverse events were similar in the two groups, ALT values rose above 3 times ULN in 0.4% vs 0.4% of subjects and none developed clinically apparent hepatitis). </i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R23">Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, Jones-Burton C. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Am J Cardiol 2011; 108: 523-30.  [<a href="/pubmed/21596364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21596364</span></a>]<div><i>(Trial of adding ezetimibe to rosuvastatin vs increasing the dose in 440 patients followed for 6 weeks; only one of 221 patients on the combination vs none on the increased dose of rosuvastatin had an ALT elevation above 3 times ULN).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R24">Toth PP, Morrone D, Weintraub WS, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM. Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6-24 weeks. Int J Clin Pract 2012; 66: 800-12.  [<a href="/pubmed/22805272" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22805272</span></a>]<div><i>(Analysis of side effects from 27 controlled trials in 22,000 patients found ALT or AST elevations above 3 times ULN in 0.35% vs 0.56% of those receiving a statin alone vs its combination with ezetimibe, and no cases of clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R25">Rosen JB, Jimenez JG, Pirags V, Vides H, Hanson ME, Massaad R, McPeters G, et al. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease. Diab Vasc Dis Res 2013; 10: 277-86.  [<a href="/pubmed/23288881" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23288881</span></a>]<div><i> (None of 321 patients who were treated with simvastatin and ezetimibe for six weeks had ALT or AST elevations above 3 times ULN).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R26">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419-25.  [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, including 2 attributed to atorvastatin and 1 to simvastatin, but none to ezetimibe).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R27">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. Ann Hepatol 2014; 13: 231-9.  [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i> (Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, none of which were attributed to ezetimibe or other cholesterol lowering agents).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R28">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52.e7.  [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 41 [5.4%] were attributed to lipid lowering agents including 2 to the combination of simvastatin and ezetimibe, but none to ezetimibe alone).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R29">Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97.  [<a href="/pubmed/26039521" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26039521</span></a>]<div><i>(Among 18,144 patients with an acute coronary syndrome and hypercholesterolemia treated with simvastatin [40 mg daily] with or without ezetimibe for a median duration of 6 years, LDL-cholesterol levels were lower [54 vs 70 mg/dL] and atherosclerotic event rates less with addition of ezetimibe [33% vs 35%], while adverse event rates were similar, including ALT or AST elevations above 3 times ULN [2.5% vs 2.3%] and no liver related serious adverse events were mentioned).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R30">Kusters DM, Caceres M, Coll M, Cuffie C, Gagn&#x000e9; C, Jacobson MS, Kwiterovich PO, et al. Efficacy and safety of ezetimibe monotherapy in children with heterozygous familial or nonfamilial hypercholesterolemia. J Pediatr 2015; 166: 1377-84.  [<a href="/pubmed/25841542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25841542</span></a>]<div><i>(Among 138 children with hypercholesterolemia who were treated with ezetimibe or placebo for 12 weeks, LDL-cholesterol decreased by 27% and ezetimibe was "well tolerated", ALT elevations above 3 times ULN occuring in only 1 patient in whom values rose to 145 U/L [bilirubin and Alk P normal] and led to early discontinuation when ALT levels remained elevated for more than a month).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R31">Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, et al.; ODYSSEYALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEYALTERNATIVE randomized trial. J Clin Lipidol 2015; 9: 758-69.  [<a href="/pubmed/26687696" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26687696</span></a>]<div><i> (Among 313 patients with hypercholesterolemia and statin intolerance treated with alirocumab or ezetimibe or atorvastatin for 24 weeks, alirocumab produced greater reductions in LDL-cholesterol than ezetimibe with slightly lower rates of myalgia than atorvastatin [25% vs 27%] and there were no ALT elevations above 3 times ULN in any group).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R32">Kim KJ, Kim SH, Yoon YW, Rha SW, Hong SJ, Kwak CH, Kim W, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther 2016; 34: 371-82.  [<a href="/pmc/articles/PMC5108468/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5108468</span></a>] [<a href="/pubmed/27506635" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27506635</span></a>]<div><i>(Among 412 pateints with hypercholesterolemia who were treated with rosuvastatin with vs without ezetimibe for 8 weeks, there were no serious adverse events and transient ALT elevations above 3 times ULN arose in only 1 patient in each group [0.5% vs 0.5%]).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R33">Jones PH, Bays HE, Chaudhari U, Pordy R, Lorenzato C, Miller K, Robinson JG. Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials. Am J Cardiol 2016; 118: 1805-11.  [<a href="/pubmed/27729106" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27729106</span></a>]<div><i> (Among 5234 patients treated with alirocumab or placebo or ezetimide in 14 controlled trials, overall adverse event rates, including serious events and deaths, were similar in the three groups, although local injection reactions were more common with alirocumab; rates of ALT elevations were also similar [2.7 and 2.9% vs 2.3% with placebo and 2.6% with ezetimibe] and there were no cases of ALT elevations with jaundice that could not be attributed to other causes [2 in patients treated with alirocumab, 2 with placebo, none with ezetimibe]).</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R34">Oikawa S, Yamashita S, Nakaya N, Sasaki J, Kono S; Effect of Fenofibrate and Ezetimibe Combination Treatment on Lipid (EFECTL) Study Investigators. Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. J Atheroscler Thromb 2017; 24: 77-94.  [<a href="/pmc/articles/PMC5225135/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5225135</span></a>] [<a href="/pubmed/27397061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27397061</span></a>]<div><i>(Among 236 Japanese pateints with hyperlipidemia treated with fenofibrate, ezetimibe or both for 52 weeks, ALT elevations occurred in 0% on ezetimibe, 3.8% on fenofibrate and 1.9% on both, and all changes were considered "comparatively mild").</i></div></div></li><li><div class="bk_ref" id="Ezetimibe.R35">El Shahawy M, Cannon CP, Blom DJ, McKenney JM, Cariou B, Lecorps G, Pordy R, Chaudhari U, Colhoun HM et al. Efficacy and safety of alirocumab versus ezetimibe over 2 years (from ODYSSEY COMBO II). Am J Cardio 2017; 120: 931-9.  [<a href="/pubmed/28750828" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28750828</span></a>]<div><i> (Among 720 patients with inadequate control of cholesterol levels with maximal doses of statins who were treated with alirocumab or ezetimibe for up to 2 years, adverse event rates were similar, ALT elevations above 3 times ULN occurred in 2.1% on alirocumab vs 0.8% on ezetimibe, but the abnormalities were usually a single value and no patient developed clinically apparent liver injury).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548095</span><span class="label">PMID: <a href="/pubmed/31643425" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643425</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Exenatide/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Ezogabine/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548095&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548095/?report=reader">PubReader</a></li><li><a href="/books/NBK548095/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548095" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548095" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Ezetimibe. [Updated 2018 Feb 18].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548095/pdf/Bookshelf_NBK548095.pdf">PDF version of this page</a> (141K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=ezetimibe+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D%3A%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Ezetimibe: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=ezetimibe" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Ezetimibe: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4858206" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4858206" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4858206" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/17587760" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.</a><span class="source">[J Atheroscler Thromb. 2007]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Davis HR, Veltri EP. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Atheroscler Thromb. 2007 Jun; 14(3):99-108. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/15864235" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.</a><span class="source">[Am Heart J. 2005]</span><div class="brieflinkpop offscreen_noflow">Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am Heart J. 2005 Mar; 149(3):464-73. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14620392" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ezetimibe: a selective cholesterol absorption inhibitor.</a><span class="source">[Pharmacotherapy. 2003]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ezetimibe: a selective cholesterol absorption inhibitor.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nutescu EA, Shapiro NL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pharmacotherapy. 2003 Nov; 23(11):1463-74. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/22353686" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia.</a><span class="source">[J Atheroscler Thromb. 2012]</span><div class="brieflinkpop offscreen_noflow">Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tamaki N, Ueno H, Morinaga Y, Shiiya T, Nakazato M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Atheroscler Thromb. 2012; 19(6):532-8. Epub 2012 Feb 22.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14604738" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor.</a><span class="source">[Clin Ther. 2003]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Jeu L, Cheng JW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Ther. 2003 Sep; 25(9):2352-87. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643425" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643425" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="&#10;                        HTOn&#10;                    "><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:01:04-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal102&amp;ncbi_phid=CE89054004657D610000000009A802E7&amp;ncbi_session=CE890540046827F1_2472SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548095%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548095&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548095/&amp;ncbi_pagename=Ezetimibe - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE890540046827F1_2472SID /projects/books/PBooks@9.2 portal102 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>